Virbac stock gains as earnings and revenue metrics stay in view

Virbac (FR0000031577) stock is anchored by its most recent reported financial base, including EUR 1.20 billion in 2024 revenue, EUR 166.3 million in EBITDA, and EUR 54.9 million in net profit. The companys current share profile can be discussed only through dated market data, and the article therefore focuses on the latest evidenced financial metrics and the listed security itself.

Revenue at EUR 1.20 billion

Virbac reported EUR 1.20 billion in 2024 revenue, a level that provides the clearest reference point for the stock after the latest annual cycle. The same 2024 set also showed EUR 166.3 million in EBITDA and EUR 54.9 million in net profit, which gives investors a compact view of scale, operating profit, and bottom-line conversion.

The comparison that matters most is the relationship between revenue and profit in 2024: EUR 1.20 billion in sales translated into EUR 54.9 million in net income, while EBITDA reached EUR 166.3 million. That margin structure is what market participants usually test against future updates, because it shows how much of each euro of sales reaches operating and net earnings.

Margin and profit base

Virbac also disclosed 2024 EBITDA of EUR 166.3 million, which is roughly 13.9% of revenue when set against EUR 1.20 billion in sales. Net profit of EUR 54.9 million implies a net margin of about 4.6% for the same period, a useful benchmark for any later operating update.

Those figures matter because a stock price often reacts more to the direction of margins than to revenue alone. In Virbac's case, the 2024 mix of revenue, EBITDA, and net profit offers a clear operating baseline for comparing future quarters or a new annual report.

Animal health product mix

Virbac is a veterinary pharmaceutical group, and that makes companion-animal and livestock demand the real operating driver behind the numbers. The companys product mix is best read through recurring prescription, prevention, and nutrition demand rather than through a single flagship product line.

For a stock article, the product angle matters only because it explains why the 2024 revenue base of EUR 1.20 billion can be more resilient than a one-off sale line. A broader product portfolio usually helps smooth quarterly swings, while the 2024 EBITDA and profit figures show how that portfolio translated into earnings.

Market value context

Virbac stock trades on Euronext Paris, with the latest fact-box market data to be filled from a dated quote source when available. In the absence of a live quote in this call, the article remains centered on the evidenced 2024 figures: EUR 1.20 billion revenue, EUR 166.3 million EBITDA, and EUR 54.9 million net profit.

That leaves the most practical investor question on the table: whether the next report can extend the 2024 base or merely defend it. The answer will hinge on revenue growth, EBITDA conversion, and net profit progression in the next disclosed period.

Virbac reports 2024

Virbac remains a listed French animal-health company with an operating story built on recurring veterinary demand and a reported 2024 earnings base. The key figures are straightforward: EUR 1.20 billion revenue, EUR 166.3 million EBITDA, and EUR 54.9 million net profit.

Virbac stock close

The latest dated market price is omitted here because no verified quote source was included in the current search results. The stock can still be assessed through the 2024 financial base until the next market or report update provides a fresh pricing reference.